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BACKGROUND: Wild-type poliovirus may be eradicated soon and under WHO GAPIII guidance, laboratory use will be discontinued or subject to strict containment. Per US Code of Federal Regulations, however, immunoglobulin lot release testing will still require use of replicating poliovirus. The suitability of S19 hyper-attenuated and apathogenic poliovirus strains as alternatives to the currently used wild-type virus in such a release assay was investigated.
STUDY DESIGN AND METHODS: S19 poliovirus strains were propagated in a commercial setting using good virological practices and maintenance of the S19 hyper-attenuated genotype was confirmed by massively parallel sequencing.
RESULTS:
The attenuated phenotype of the produced S19 stocks was confirmed in a highly sensitive mousemodel. Equivalency in performance was seen in the lot release assay for the S19 and wild-type polioviruses.
CONCLUSION:
The deployment of such hyperattenuated and thoroughly characterized S19 stocks in these and other essential activities might reconcile final containment measures with continued safe use of poliovirus.
T he ongoing Global Polio Eradication Initiative (GPEI) is the largest public health intervention ever undertaken. Driven by the World Health Organization (WHO), this initiative has reduced the number of poliomyelitis cases from an estimated 350,000 in 1988 to about 100 in 2017, saved more than 1.5 million lives, and prevented disease in an estimated 16 million people world-wide. 1 Of the three poliovirus (PV) serotypes, wild-type 2 was declared eradicated in 2015 and therefore PV type 2 (PV2) must now be handled at high containment, ideally in PV-essential facilities that adhere to the WHO developed Global Action Plan (GAPIII). 2 Facilities must be located in areas with low transmission potential for wild-type PV and adhere to stringent criteria with respect to restriction of all Polio work to laboratories that operate under biosafety level 3 (BSL3), with additional measures implemented. 2 Laboratories that do not comply with the required containment conditions must discontinue use of all PV2 materials, and these restrictions will be extended to the other PV serotypes once eradication has been achieved, likely in the near future. The need to restrict the number of PV-essential facilities that operate under strict biosafety measurements is essential to maintain PV eradication, yet contradictory to a US Food and Drug Administration (FDA) requirement for human immunoglobulins. Intravenous immunoglobulin (IVIG) is a therapeutic preparation with application as antibody replacement therapy in persons with primary immunodeficiency disorders, as well as for the treatment of a range of auto-immune conditions, and an essential medicine as per WHO. 3, 4 The Code of Federal Regulations requires neutralization testing against PV for functional final lot release of immunoglobulin preparations, 5 for which replicating PV is required. These lot release assays need to be done for every lot, and are commonly performed in quality control (QC) laboratories, most of which do not currently comply with GAPIII and could not do so in the short term. 6 Use of replicating PV is required for these cell culture-based neutralization assays and, as long as CFR 21.640.104 remains in force, these assays will need to continue to ensure IVIG supply. The use of PV strains which are non-infectious for humans might offer an alternative, as these strains might qualify for exemption from containment according to GAPIII and allow for handling at a lower BSL, a compromise that would help to safeguard the success of the Polio eradication campaign and at the same time allow for continued use of PV in commercial laboratories under good virological practices, e.g., for IVIG lot release. The S19 hyper-attenuated PV strains were engineered on the basis of the attenuated Sabin strains currently used for vaccine production and include further mutations in the domain V of the 5 0 non-coding region that render these strains hyper-attenuated and genetically stable, while able to grow to high titers in cell culture, but unable to revert to a virulent phenotype and are therefore considered non-infectious for humans. 7 No changes were made to the capsid proteins so the surface structures of the S19 particles should be identical to the respective wild-type strains and neutralization by polyclonal antibodies, such as IVIG, is therefore expected to be equivalent. The study reported here aimed to evaluate whether a hyper-attenuated S19 PV strain might be a suitable alternative to the currently used wild-type PV in the QC assays required for IVIG lot release, which would allow the gap to be bridged between necessary PV containment after successful eradication and the CFR requirement, for the supply of an essential medicine.
METHODS
Hyper-attenuated S19 and wild-type poliovirus propagation and characterization
Two hyper-attenuated S19 strains "S19/MahP1/N18S" (S19/Mah) and "S19/SktP1/N18S" (S19/Skt), which carry the capsid sequence of type 1 strain "Mahoney" and type 3 strain "Saukett", respectively and which were optimized for growth on Vero cells, 7 a cell line typically used in QC assays, were cultivated at Shire using good virology practices. Using a stringent stock production system, virus passage was limited to a maximum of 4 sub-cultivations, which resulted in ample stock supply. To assess the genetic status of the prepared hyper-attenuated virus stocks, massively parallel sequencing was done (see below). The infectious virus titers were determined using a median tissue culture infectious dose (TCID 50 ) assay, where serial 0.5 log dilutions of the viruses were applied to microtiter plates seeded with Vero cells, incubated at 33 C with 4.5% CO 2 and evaluated for cytopathic effect (CPE) microscopically. Wild-type PV type 1 strain Mahoney derivate "LSa" (wt/Mah; Cat. no. #VR-59; American Type Culture Collection, Manassas, Virginia) was propagated using similar virological techniques.
Massively parallel sequencing of hyper-attenuated S19 poliovirus stocks
Variants present in the genomes of the hyper-attenuated stocks after 4 passages in Vero cells were identified by single nucleotide polymorphism (SNP) analysis of Illumina sequencing reads at a coverage of > 5,000. In addition, the presence of double nucleotide polymorphisms (DNPs) in critical stems of RNA domain V (nt 471-538; Fig. 1 ) that resulted in the replacement of a UA(AU) base-pair with a CG(GC) pair were analyzed at a coverage of > 500,000. This assay allowed highly sensitive identification of any mutations that could affect the hyper-attenuated phenotypes of the S19 strains. RNA was purified from virus stocks using Roche High Pure viral RNA kits. Water only controls were extracted, amplified and sequenced in parallel with each set Genomic sequencing libraries were prepared using Nextera XT reagents (Illumina) and the manufacturer's protocol and sequenced on a MiSeq using a 2 × 251 paired-end v2 Flow Cell (Illumina). Quality (Q30) trimming and assembly to plasmid reference sequences were carried out as previously described 9 using Geneious R7 (Biomatters) software. SNPs present at ≥ 0.5% in both replica amplicons were identified. Domain V libraries, which did not require tagmentation, were sequenced in the same way except at higher coverage. After quality trimming as above, sequences were mapped to a library of 19 (68 nt) DNA sequences comprising S19 domain V and all possible double nucleotide variants of S19 domain V where a critical UA(AU) base-pair was replaced with a CG(GC) pair (Fig. 1) . Mapping was done with a minimum overlap of 68 nt and a minimum overlap identity of 100%.
Neutralization assay for poliovirus antibodies
PV neutralizing antibody titers were determined for five IVIG lots (Gammagard Liquid, 10%; Shire, Lexington, MA) in neutralization assays that used the hyper-attenuated PV strain S19/Mah in direct comparison to the wt/Mah. As IVIG lots have similar titers for PV, the immunoglobulin samples were serially diluted in cell culture medium, to generate samples which allow for dose-response determination in the neutralization assay. The dilutions were mixed with 10 2.7 TCID of infective PV and the virus-antibody mixtures inoculated onto Vero cells and incubated for 5-7 days, when the cells were inspected microscopically for the presence of degenerative changes. The absence of such CPE indicated the presence of PV neutralizing antibodies in the sample and the dilution that provided 50% protection of the cell culture from infection was described as the μNT 50 . Each test included the current reference material designated by the Center for Biologics Evaluation and Research (CBER, lot 176) or a reference material that had been calibrated against CBER lot 176 and the μNT 50 results were subsequently transformed to CBER lot 176 ratios.
Intraspinal inoculation of TgPVR mice
The neurovirulence of S19 stocks was assessed in a paralytic dose 50% (PD 50 ) assay by intraspinal inoculation of transgenic mice carrying the human receptor for PV, as described previously. 
Data analysis
Statistical analysis (linear regression analysis, paired two-tailed t-test) was done using GraphPad Prism v.5.01, GraphPad Software, CA, USA. TCID 50 titers were calculated according to the Poisson distribution and expressed as log 10 [TCID 50 /mL]. Neutralization titers (50%; μNT 50 ) were calculated using the statistical approximation method of Spearman-Kärber and a validated in-house software program. CBER lot 176 ratios were calculated using Microsoft Excel.
RESULTS
Passage of the two PV strains S19/Mah and S19/Skt on Vero cells in the laboratories at Shire resulted in consistent increase in tissue-culture infectious titers, from an initial 6.2 and 5.4 log TCID 50 /mL after the first passage to 7.4 and 8.0 log TCID 50 /mL after the fourth passage, respectively. The high-titer fourth passage PV S19 stocks were subjected to analysis by massively parallel sequencing, which specifically aimed at an assessment of the hyper-attenuated status (S19) of the domain V region (Fig. 1 ) of the PV stock preparations to confirm retention of attenuating sequences, as well as of potential variations within the coding region, most importantly of the sequences encoding the capsid proteins (VP4-VP1), to confirm maintenance of serotype identity and antigenic structure. For the fourth passage stock of S19/Mah this analysis confirmed that no significant reversions in the domain V region occurred (Table 1) , i.e., the hyperattenuated S19 status of the S19/Mah stock preparation was maintained. No significant genetic variations within the capsid encoding regions were seen. The 5 amino acid changes that were identified for the capsid-encoding regions were present at frequencies below 7% (Table 2 ) and therefore unlikely influence neutralization titers. The same analysis for the fourth passage S19/Skt stock revealed the presence of a low level of variants at base-pair positions 481:530, at a frequency of approx. 1 in 24,500 (Table 1 ; sensitivity of analysis approx. 1 in 350,000). These variants are equivalent, in terms of numbers of UA vs CG base-pairs, to the S18 virus, which is also hyper-attenuated. 7 The attenuated phenotypes of the strains were measured by PD 50 assay in transgenic mice expressing the human PV receptor, a highly sensitive test in which the PD 50 of wild strains are < 1.0 log 10 TCID 50 . 7 Attenuation phenotypes of the fourth passage S19/Mah and S19/Skt stocks produced at Shire were unchanged compared to the original NIBSC stocks with no mice paralyzed at the highest dose that was inoculated (Table 3) . Analysis of the capsid-coding region showed the presence of an NàK variant at codon 144 in the Skt VP1 region at a level which constituted the majority of the population (86.20%; Table 2 ). Due to the heterogeneity of the passage 4 S19/Skt stock this variant was not further evaluated in the QC lot release assay. Other variants were identified in the non-structural coding regions of both passage 4 stocks, at frequencies of 0.5-30%, which are unlikely to affect attenuation or antigenic characteristics but which may have influenced titers in cell culture.
In neutralization assay testing, a highly significant correlation (p < 0.0001; R 2 = 0.88; Fig. 2A ) was seen between tests conducted with the wt/Mah and S19/Mah strains when different sample dilutions were tested, in an assay equivalent to IVIG QC release testing according to CFR 21, 640.104. CBER lot 176 ratios obtained with the wt/Mah strain tended to be somewhat higher than the ratios obtained with the S19/Mah, which was statistically not significant (p = 0.08, paired t-test). The release criterion for type 1 PV is 0.17 x CBER lot 176 for 10% IVIG (corrected for protein content) and each lot tested was above this criterion by at least 3.1-fold, where the arithmetic mean was 0.69 x CBER lot 176 (4.1-fold above release criterion limit) for S19/Mah and 0.76 x CBER lot 176 (4.5-fold above release criterion limit) for wt/Mah (Fig. 2B) .
DISCUSSION
Activities that require the use of live PV will need to continue for some time beyond final containment. While only destruction of the virus would eliminate any risk of accidental release, a switch to alternative, hyper-attenuated PV strains that are unable to infect humans may equally minimize the risks of transmission and disease in the event of facility-associated dissemination into the environment, a strategy that was already proposed by the WHO and FDA more than a decade ago. 11, 12 Replication incompetent pseudoviruses 13, 14 or hyperattenuated PV strains 12, [15] [16] [17] have been developed and their use in vaccine production, immunogenicity studies, immunotherapy, monitoring of the environment, or neutralizing antibody titers has been proposed. The feasibility to use such * See Fig. 1 : base-pair positions according to numbering in Sabin 3 strain; bold highlights base-pairs that were substituted to obtain S19 status. † Sum of three independent analyses. hyper-attenuated strains for vaccine production has been shown 18 and was confirmed for the monitoring of PV neutralizing antibody titers in the QC of immunoglobulin, another essential medicinal, in this work. Using standard virological practices it was possible to produce S19 stocks with infectivity titers that were suitable for QC release testing, the only special requirement for the handling of these strains stemming from their genetically modified nature, i.e., laboratories licensed for work with GMOs might be required. Conservation of sequences in domain V (responsible for attenuation) as well as in capsid coding regions was confirmed by massively parallel sequencing for the S19/Mah stock and maintenance of the hyper-attenuation phenotype was confirmed in an highly sensitive mousemodel, a level of scrutiny which has never before been applied to reagents in a QC release assay but which was considered warranted in this case, to ensure everything possible is done to guarantee safe work with S19 strains in a GAPIII world.
The observed NàK mutation in the VP1 structural protein coding region in the S19/Skt stock has previously been associated with adaption to growth on Vero cells (Macadam et al., unpublished) . In combination with the low levels of S18-like variants detected, although these changes per se would still make for a hyper-attenuated, and therefore safe, virus stock, the produced S19/Skt stock was considered potentially unsuitable for further evaluation in a QC release assay. In IVIG QC release testing, a statistically not significant trend towards slightly lower CBER lot 176 ratios was seen with S19/Mah in comparison to wt/Mah. The obtained ratios were at an acceptable level, i.e., significantly above the required lot release criterion and the S19 strain therefore considered a possible replacement for the wild-type strain in the testing regime for immunoglobulins. However, before such a switch in a critical test substance can be validated and submitted to the FDA for approval in IVIG lot release testing, the hyper-attenuated strains need to be exempted from GAPIII requirements. At present, GAPIII deals explicitly with the processes and facility requirements for work with wild and vaccine PV strains after eradication and the handling of hyper-attenuated strains was not differentiated, i.e., the S19 strains therefore currently classify as wild-type PV to which all GAPIII conditions apply. The potential for development of novel safer strains of PV that could, in principle, be safely handled under lower containment conditions is recognized 2 and ultimately, the WHO will have the final decision on whether attenuated strains of PV are safe enough to use outside some of the containment conditions described in GAPIII. A first recommendation that S19-Sabin 2 strains can be used outside of GAPIII containment requirements was recently published, 19 and is expected to be extended to the other S19 serotypes as and when their wild-type counterpart becomes extinct. Here, we showed that the S19 strains can be a suitable alternative to wild-type PV in IVIG lot release testing. It is likely that the strains will also prove suitable for other activities requiring live virus such as seroprevalence studies, vaccine potency assays, and validation of cell-sensitivity. As feasibility for their use in vaccine production has previously been shown, 18 these hyper-attenuated strains now need to be recognized as safe alternatives. As long as good virological practice is maintained, based on a seed lot system with stocks characterized using the sensitive assays described here, S19 strains should be exempt from full GAPIII containment requirements in order to allow for their establishment in the activities that will need to continue in the future, which will in fact contribute to final containment and aid in achieving and maintaining a PV free world.
ACKNOWLEDGMENTS
The contributions of the entire Global Pathogen Safety team, most notably Veronika Sulzer and Melanie Graf (cell culture) and Eva Ha conducted the experiments with wild-type PV.
